KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Non-Current Debt (2016 - 2020)

Historic Non-Current Debt for Neogenomics (NEO) over the last 8 years, with Q1 2020 value amounting to $90.6 million.

  • Neogenomics' Non-Current Debt rose 536.08% to $90.6 million in Q1 2020 from the same period last year, while for Mar 2020 it was $90.6 million, marking a year-over-year increase of 536.08%. This contributed to the annual value of $91.8 million for FY2019, which is 449.36% up from last year.
  • Neogenomics' Non-Current Debt amounted to $90.6 million in Q1 2020, which was up 536.08% from $91.8 million recorded in Q4 2019.
  • Over the past 5 years, Neogenomics' Non-Current Debt peaked at $94.2 million during Q2 2019, and registered a low of $52.2 million during Q3 2016.
  • Its 5-year average for Non-Current Debt is $75.8 million, with a median of $70.1 million in 2016.
  • Its Non-Current Debt has fluctuated over the past 5 years, first skyrocketed by 3424.62% in 2016, then crashed by 599.02% in 2018.
  • Neogenomics' Non-Current Debt (Quarter) stood at $70.1 million in 2016, then dropped by 5.04% to $66.6 million in 2017, then soared by 31.92% to $87.9 million in 2018, then grew by 4.49% to $91.8 million in 2019, then fell by 1.33% to $90.6 million in 2020.
  • Its last three reported values are $90.6 million in Q1 2020, $91.8 million for Q4 2019, and $93.0 million during Q3 2019.